Focused Wealth Management Inc Makes New Investment in Prothena Co. plc (NASDAQ:PRTA)

Focused Wealth Management Inc acquired a new position in Prothena Co. plc (NASDAQ:PRTA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 32,129 shares of the biotechnology company's stock, valued at approximately $445,000. Focused Wealth Management Inc owned approximately 0.06% of Prothena at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its holdings in Prothena by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company's stock valued at $173,000 after purchasing an additional 4,026 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new stake in Prothena during the fourth quarter valued at approximately $159,000. Intech Investment Management LLC bought a new stake in Prothena in the third quarter worth $210,000. XTX Topco Ltd bought a new stake in shares of Prothena in the 3rd quarter worth about $260,000. Finally, Orion Portfolio Solutions LLC lifted its stake in Prothena by 4.4% in the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock worth $293,000 after purchasing an additional 739 shares during the last quarter. 97.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PRTA has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Prothena from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. Bank of America cut their price target on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a report on Thursday, December 19th. Chardan Capital assumed coverage on shares of Prothena in a research note on Friday, December 20th. They issued a "buy" rating and a $40.00 target price for the company. Oppenheimer boosted their price target on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research note on Friday, February 7th. Finally, HC Wainwright reissued a "buy" rating and set a $48.00 target price (down previously from $84.00) on shares of Prothena in a report on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.50.

Prothena Trading Up 0.2 %

PRTA stock traded up $0.03 during trading on Wednesday, hitting $13.82. 249,411 shares of the company's stock were exchanged, compared to its average volume of 372,822. Prothena Co. plc has a 52-week low of $11.70 and a 52-week high of $31.03. The stock has a market capitalization of $743.65 million, a price-to-earnings ratio of -5.57 and a beta of 0.08. The business has a 50-day moving average price of $14.25 and a two-hundred day moving average price of $17.14.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.08. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The business had revenue of $0.97 million during the quarter, compared to analysts' expectations of $1.22 million. During the same period last year, the firm earned $0.38 EPS. The company's quarterly revenue was down 98.9% compared to the same quarter last year. On average, equities research analysts anticipate that Prothena Co. plc will post -2.24 earnings per share for the current fiscal year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.